Učitavanje...

Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.

Thirty-six consecutive patients with breast cancer and liver metastases with abnormal liver biochemistry were treated with epirubicin 25 mg m-2 i.v. weekly. No dose modification was made for abnormal liver biochemistry, but dose intensity was adjusted by delaying treatment according to myelosuppress...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Twelves, C. J., O'Reilly, S. M., Coleman, R. E., Richards, M. A., Rubens, R. D.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 1989
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2247276/
https://ncbi.nlm.nih.gov/pubmed/2605102
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!